SPOTLIGHT -
Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL
Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.
Frederick Locke, MD, Reviews the Next Steps for Axi-Cel in LBCL
Frederick Lock, MD, spoke about how future research regarding axicabtagene ciloleucel for patients with large B-cell lymphoma will progress.
Frederick Locke, MD, Talks Unmet Needs Reduced by Axi-Cel Use in LBCL
Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.
Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL
Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.
Frederick Locke, MD, and Michael Jain, MD, PhD, on Why Some Patients With Lymphoma Do Not Respond to Cellular Immunotherapy
CancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.
Investigating CAR T-Cell Therapy in Patients With DLBCL, FL, and Other Lymphomas
In this interview, Dr. Frederick Locke discusses the promise of CAR T-cell therapy for lymphomas, and how this gene therapy could offer hope for patients who don't respond to standard treatments.
CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma
This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.
